INDP News and Press, Indaptus Therapeutics Inc. From 11/15/21

NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update. “The third quarter was transformative f...

Indaptus Therapeutics is advancing the Decoy bacteria triggered immune response technology for cancer and viral indications. The company was formed from the reverse merger of Intec Pharma and Decoy Biosystems. Shares of the company commenced trading on Nasdaq on August 4, 2021. ...

One of the most dramatic examples of the sudden dominant interest of retail market participants is the massive short squeezes we are seeing in stocks such as GameStop Corp (NYSE:GME) and AMC Entertainment Holdings Inc (NYSE:AMC). This scenario – a raging bull market that casts advantag...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Indaptus Therapeutics (NASDAQ: INDP ) stock are taking off on Wednesday after positive news regarding the firm’s HBV and HIV treatments. Source: Shutterstock The United States Patent and Tradema...

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s platform technology. ...